News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Seres Health To Present Clinical Findings At ICAAC 2014 Conference

8/28/2014 1:27:48 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Aug. 28, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, announced today that Dr. David Cook, Seres' Executive Vice President of R&D and Chief Scientific Officer, will be presenting at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The presentation will highlight the scientific and medical implications of SER-109, a novel mixture of bacterial spores derived from the human microbiome, and provide final data on Seres' single-arm, open-label clinical trial of SER-109.

The presentation is scheduled for Monday, September 8, 2014, from 3:00 p.m. 5:30 p.m. ET in meeting room 151B at the Walter E. Washington Convention Center in Washington, DC. Dr. Cook's presentation will be part of the session "Clostridum difficile: Pathogenesis, Immune Response and Therapy."

About SER-109

SER-109 is the lead Seres Health Ecobiotic® microbial therapeutic in clinical testing for the treatment of recurrent Clostridiumdifficile infection (CDI). SER-109 was developed utilizing the Seres Health Microbiome Therapeutics platform that provides deep insight into the ecologies of disease and then identifies microbial compositions that can catalyze a shift to health. CDI is a rapidly growing problem associated with antibiotic use. Approximately 100,000 - 150,000 of CDI patients in the U.S. have more than one recurrence. Multiple recurrent CDI has recently been designated as an Orphan Drug Indication by the FDA.

About Seres Health

Seres Health is a clinical-stage therapeutics company focused on discovering and developing Ecobiotic® therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases. Seres recently announced a research agreement with Mayo Clinic and has received over $20 million in funding to date. For more information, please visit


For Seres Health: Emily Rossi
Ruder Finn

SOURCE Seres Health

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus